CVE:ZOM Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis C$0.28 -0.02 (-6.56%) As of 02/5/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ZOM alerts:Sign Up Key Stats Today's RangeC$0.29▼C$0.2950-Day RangeC$0.29▼C$0.2952-Week RangeC$0.29▼C$1.50Volume4,800 shsAverage Volume2,858 shsMarket CapitalizationC$36.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.Read More… Remove Ads Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address ZOM Stock News HeadlinesZomedica Corp. trading halted, news pendingMarch 4, 2025 | markets.businessinsider.comZomedica Pharmaceuticals (ZOM) Receives a Buy from Noble FinancialFebruary 7, 2025 | markets.businessinsider.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 31, 2025 | Brownstone Research (Ad)Phio Pharmaceuticals Corp.September 14, 2024 | wsj.comZomedica Corp. (ZOM) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comZomedica Corp. (AMEX:ZOM) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comZomedica Corp Ordinary Shares ZOMNovember 19, 2023 | morningstar.comZomedica Stock (AMEX:ZOM), DividendsMay 10, 2023 | benzinga.comSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How have ZOM shares performed this year? Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the start of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29. View the best growth stocks for 2025 here. How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)? Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Ocugen (OCGN), T2 Biosystems (TTOO), Meta Platforms (META), Bionano Genomics (BNGO), Onconova Therapeutics (ONTX), Biocept (BIOC) and Ford Motor (F). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolCVE:ZOM CIKN/A Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.91 Current Ratio15.31 Quick Ratio15.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.05 per share Price / Cash Flow5.38 Book ValueC$0.05 per share Price / Book5.82Miscellaneous Outstanding Shares128,872,000Free FloatN/AMarket CapC$36.73 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (CVE:ZOM) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Pharmaceuticals Corp. (ZOM.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica Pharmaceuticals Corp. (ZOM.V) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.